LRRK2 and Parkinson disease: Our data substantiate a role for increased LRRK2 kinase activity in at least some idiopathic PD patients and suggest that blood-based PD patient stratification according to cohesion deficits may hold promise in the context of clinical trials with LRRK2 inhibitors.